Adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine among≥18-year-old individuals with human immunodeficiency virus infection:an observational study in Xihu district of Hangzhou city
Objective To determine incidences of adverse events following vaccination with 23-valent pneumococcal polysaccharide vaccine(PPV23)in ≥ 18-year-old individuals living with human immunodeficiency virus(HIV).Methods We enrolled HIV-infected adults over 18 years of age from vaccination clinics in Xihu district of Hangzhou city and followed them up for adverse events 0-28 days after receiving one dose of PPV23 to determine incidences.Results The overall incidence of adverse events 0-28 days after one dose of PPV23 vaccination was 32.89%(148/450),with local and systemic adverse event rates of 31.33%(141 cases)and 2.22%(10 cases).Incidences for injection-site pain,redness,and swelling were 24.89%(112 cases),7.33%(33 cases),and 10.00%(45 cases).Incidences for fever and dizziness were 2.00%(9 cases)and 0.22%(1 case).No serious adverse events were reported.Conclusion The incidence of adverse events following PPV23 vaccination of people≥18 years of age living with HIV was less than expected,and symptoms of adverse events were mild.